- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02333123
Aspirin for Venous Ulcers: Randomised Trial (AVURT) (AVURT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The mainstay of treatment of leg ulcers is graded compression therapy to squeeze the fluid out of the leg and venous system. This has been shown to be effective in many clinical trials. However, despite this treatment patients take many months to heal (with median healing times of approximately 12 weeks in previous trials) and for some patients compression therapy does not result in resolution of their leg ulcers. The use of compression (as well as dressings largely to manage the wound exudate) can be expensive as nurse time is required to change bandages which can be required weekly or more frequently. Furthermore, for many patients the compression therapy is uncomfortable (sometimes painful) and inconvenient for everyday life (compression is bulky and dressings have to be changed several times weekly). If other treatments were able to reduce the time to healing then this would be a significant breakthrough.
Results from two earlier small trials suggest aspirin may be of benefit. However this trials were poorly designed and reported. The present study will evaluate whether the addition of 300mg of daily aspirin to standard evidence based therapies reduces the time to healing of chronic venous leg ulceration using a more rigorous design. The study will also establish the feasibility of satisfactory participant recruitment for a bigger trial, and whether participants are compliant with their aspirin therapy. The safety of aspirin in this patient population will also be monitored.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Newcastle Upon Tyne, United Kingdom, NE3 3HD
- Freeman Hospital
-
-
Castle hill hosp
-
Cottingham, Castle hill hosp, United Kingdom, HU16 5JP
- Hull & East Yorkshire Hospital NHS Trust
-
-
London
-
Tooting, London, United Kingdom, SW17 0QT
- St George's University Hospitals NHS Foundation Trust
-
-
N.Yorkshire
-
Harrogate, N.Yorkshire, United Kingdom
- Harrogate & district NHS Trust
-
-
Sussex
-
Brighton, Sussex, United Kingdom, BN2 3EW
- Brighton General Hosp
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Those with at least one chronic venous leg ulcer - where chronic venous leg ulceration is defined as any break in the skin which has either: a) been present for more than six weeks, or b) occurred in a person with a history of venous leg ulceration. Ulcers will be considered purely venous if clinically no other etiology was suspected. For this the ulcer must be venous in appearance (i.e. moist, shallow, of an irregular shape) and lie wholly or partially within the gaiter region of the leg. If the patient has more than one ulcer we will choose the largest ulcer as the 'index' lesion for purposes of the analysis.
- Ulcer area > 1 square cm
- Participants must have had an ankle brachial pressure index (ABPI) ≥ 0.8 taken within the previous three months. When the ABPI is incompressible other forms of assessment including peripheral pulse examination / toe pressure / duplex ultrasound in combination with clinical judgement to be used to exclude PAD
- Aged ≥ 18 years (no upper age limit)
- Able and willing to provide informed consent
- Ulcer duration > 6 weeks or prior history of venous ulceration.
Exclusion Criteria:
- Unable to provide consent
- Unwilling to provide consent
- Foot (below the ankle) ulcer
- A leg ulcer of non-venous aetiology (i.e. arterial)
- Ankle-brachial pressure index (ABPI) <0.8
- Current regular use of aspirin (as may be randomised to placebo)
- Previous intolerance of aspirin / contraindication to aspirin (decision made according to the prescribers' clinical judgement)
- Prohibited medication: Probenecid
- Known lactose intolerance (as placebo contains lactose)
- Pregnant/lactating women
- Currently participating in another study evaluating leg ulcer therapies.
- Another reason that excluded them from participating within this trial (decision made according to the nurses' or prescribers' clinical judgment )*
- Previously been recruited in to this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aspirin
Aspirin 300mg capsule by mouth once a day for 24 weeks.
|
Each 300mg aspirin capsule will contain over-encapsulated 4 x Aspirin 75mg tablets.
|
Placebo Comparator: Placebo
Placebo capsule (for aspirin 300mg capsule) by mouth once a day for 24 weeks.
|
Each placebo capsule will contain a lactose and magnesium stearate blend, and will appear identical in weight, colour and size to the matched aspirin capsules.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to healing of the reference ulcer (the largest eligible ulcer)
Time Frame: 25 weeks
|
25 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ulcer size (area) measured in square cm
Time Frame: 25 weeks
|
25 weeks
|
|
Recurrence of reference ulcer
Time Frame: 25 weeks
|
Proportion of participants with a recurrence of reference ulcer.
Time to recurrence.
|
25 weeks
|
Ulcer related pain using the VAS Score
Time Frame: 5 weeks
|
5 weeks
|
|
Treatment concordance: number of participants completing the course of treatment
Time Frame: 24 weeks
|
Proportion of participants completing the course of treatment up to healing or planned trial exit.
The number of capsules taken.
Nurse's assessment of participant's compliance with recommended compression therapy.
|
24 weeks
|
Resource use
Time Frame: 27 weeks
|
Number and duration of all leg ulcer-related appointments with health professionals (including wound related in-patient stays ).
Number of and types of dressings used.
|
27 weeks
|
Number of adverse events
Time Frame: 27 weeks
|
Number of participants with at least one event.
Total number of events.
|
27 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Robert J Hinchliffe, MD, FRCS, St George's Healthcare NHS Trust
Publications and helpful links
General Publications
- Helen T, Liz C, Laura C, Illary S, Martin B, Hannah B, Ian C, Jo D, Chris F, Rachael F, Rhian G, Keith H, Alison L, Ellie L, Catriona MD, Christine M, Debbie R, Gerard S, David T, Peter V, Laurie W, Robert H. Aspirin versus placebo for the treatment of venous leg ulcers-a phase II, pilot, randomised trial (AVURT). Trials. 2019 Jul 26;20(1):459. doi: 10.1186/s13063-019-3480-7.
- Tilbrook H, Clark L, Cook L, Bland M, Buckley H, Chetter I, Dumville J, Fenner C, Forsythe R, Gabe R, Harding K, Layton A, Lindsay E, McDaid C, Moffatt C, Rolfe D, Sbizzera I, Stansby G, Torgerson D, Vowden P, Williams L, Hinchliffe R. AVURT: aspirin versus placebo for the treatment of venous leg ulcers - a Phase II pilot randomised controlled trial. Health Technol Assess. 2018 Oct;22(55):1-138. doi: 10.3310/hta22550.
- Tilbrook H, Forsythe RO, Rolfe D, Clark L, Bland M, Buckley H, Chetter I, Cook L, Dumville J, Gabe R, Harding K, Layton A, Lindsay E, McDaid C, Moffatt C, Phillips C, Stansby G, Vowden P, Williams L, Torgerson D, Hinchliffe RJ. Aspirin for Venous Ulcers: Randomised Trial (AVURT): study protocol for a randomised controlled trial. Trials. 2015 Nov 10;16:513. doi: 10.1186/s13063-015-1039-9.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Skin Ulcer
- Varicose Veins
- Ulcer
- Leg Ulcer
- Varicose Ulcer
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Aspirin
Other Study ID Numbers
- 14.0096
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Leg Ulcer
-
Tactile MedicalCompletedVenous Insufficiency | Venous Leg Ulcer | Chronic Venous Insufficiency | Venous Ulcer | Venous Stasis UlcerUnited States
-
Gloucestershire Hospitals NHS Foundation TrustNot yet recruitingLeg Ulcer | Venous Leg Ulcer | Venous Insufficiency of Leg | Venous Ulcer
-
DeRoyal Industries, Inc.Royal College of Surgeons, Ireland; Enterprise Ireland; Tyndall National InstituteCompletedVenous Leg Ulcer | Venous Insufficiency of LegIreland
-
Chang Gung Memorial HospitalRecruitingVenous Leg Ulcer | Venous Insufficiency of Leg | Venous Occlusion | Contrast Media ReactionTaiwan
-
Ortec InternationalCompletedVenous Leg Ulcer | Venous Stasis UlcerUnited States
-
Firstkind LtdTerminatedLeg Ulcer | Venous Leg Ulcer | Venous UlcerCanada
-
W.L.Gore & AssociatesRecruitingVenous Leg Ulcer | Venous Stasis | Venous Stenosis | Venous Occlusion | Venous Ulcer | Venous Thromboses | Venous Disease | Vein Thrombosis | Vein Occlusion | Vein DiseaseUnited States
-
W.L.Gore & AssociatesRecruitingVenous Leg Ulcer | Venous Stasis | Venous Stenosis | Venous Occlusion | Venous Ulcer | Venous Thromboses | Venous Disease | Vein Thrombosis | Vein Occlusion | Vein DiseaseUnited States, Australia, Germany, Italy, United Kingdom, New Zealand, Ireland
-
Firstkind LtdCompletedLeg Ulcer | Venous Leg Ulcer | Wound | Wound Leg | Leg Ulcers VenousUnited Kingdom
-
Mansoura UniversityActive, not recruitingVaricose Veins | Venous Insufficiency | Venous Leg Ulcer | Venous RefluxEgypt
Clinical Trials on Aspirin
-
The First Affiliated Hospital with Nanjing Medical...UnknownCoronary AtherosclerosisChina
-
Seoul National University HospitalCKD Pharmaceutical LimitedCompleted
-
Queen Mary University of LondonCancer Research UK; Barts and the London School of Medicine and DentistryCompletedProstate CancerUnited Kingdom
-
FANG HERecruitingPreeclampsia | Perinatal HaemorrhageChina
-
University of VigoRecruiting
-
Seoul National University HospitalCompletedCoronary Artery DiseaseKorea, Republic of
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingPulmonary Disease, Chronic ObstructiveUnited States
-
Seoul National University HospitalCompletedHealthyKorea, Republic of
-
PLx PharmaCompletedDiabetes Mellitus, Type 2United States
-
BayerCompleted